Operating Company Healthcare

Apotex

Toronto, Ontario, Canada

Global pharmaceutical company headquartered in Toronto, Canada. Portfolio includes more than 550 generic, biosimilar and innovative medicines and more than 225 natural health products, serving people across the Americas via pharmaceutical licensing and product acquisitions.

Focus Areas
Generic medicines, Biosimilars, Branded pharmaceuticals
Website
apotex.com

Tracked deals

4

4 tracked deals across 2024-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

2 buyout · 2 divestiture

Apotex Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Apotex. 1 2024 1 2025 ~3 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • RedHill Biopharma Divests Talicia to an Apotex Subsidiary for $18M Upfront Plus Milestones
    August 31, 2026
    Buyer
    Apotex Health Corp. (subsidiary)
    Target
    Talicia
    Seller
    RedHill Biopharma Ltd.
    Industry
    Pharmaceuticals
    Location
    Israel
    Type
    Divestiture

    RedHill Biopharma divested its 70% interest in the Talicia business to a subsidiary of Apotex Health for $18 million upfront cash, plus up to $35 million in worldwide net sales milestone payments. The company said proceeds will strengthen liquidity and fund the next stage of RedHill’s gastrointestinal commercial expansion, including scaling its GI franchise and pursuing new high-value FDA-approved opportunities.

  • Apotex Acquires Cumberland Pharmaceuticals' U.S. Branded Portfolio for $100 Million
    April 23, 2026
    Buyer
    Apotex, Apotex Health Corp.
    Target
    Cumberland Pharmaceuticals Inc.
    Seller
    Cumberland Pharmaceuticals Inc.
    Industry
    Pharmaceuticals
    Location
    Tennessee, United States
    Type
    Divestiture

    Apotex entered into an agreement with Cumberland Pharmaceuticals to integrate Cumberland’s U.S. branded pharmaceutical business into Apotex. Under the terms, Apotex will acquire Cumberland’s line of branded pharmaceuticals for $100 million in cash, while Cumberland retains its pipeline candidates (including ifetroban) and its majority ownership in Cumberland Emerging Technologies Inc.

  • Apotex Acquires CanPrev
    February 3, 2025
    Buyer
    Apotex Inc.
    Target
    CanPrev
    Seller
    Franco Salituro, Tanya Salituro
    Industry
    Consumer Products
    Location
    Ontario, Canada
    Type
    Buyout

    Apotex Inc. has acquired CanPrev, a Canadian natural health company known for its CanPrev, Cyto-Matrix, and Orange Naturals brands. The deal brings Apotex into the Canadian health and wellness consumer market, expanding its channels into health food stores, naturopathic/professional channels, grocery retail and strengthening its consumer health product portfolio.

  • Apotex Acquires Searchlight Pharma
    April 2, 2024
    Buyer
    Apotex Inc.
    Target
    Searchlight Pharma Inc.
    Industry
    Pharmaceuticals
    Location
    Quebec, Canada
    Type
    Buyout

    Apotex Inc. has completed the acquisition of Montreal-based Searchlight Pharma Inc., integrating Searchlight as Apotex's Specialty Pharma Division to expand its branded and specialty pharmaceutical capabilities. The deal adds Searchlight's portfolio of more than 60 products across women's health, dermatology, allergy, pain management and hospital specialty markets, and strengthens Apotex's commercial footprint in Quebec and across the Americas.

Related Acquisition Pages

Pharmaceuticals Buyers & Acquisitions 3 tracked deals by Apotex. Consumer Products Buyers & Acquisitions 1 tracked deal by Apotex. Acquisitions in Tennessee 1 tracked deal by Apotex.

Related articles

Selling a company? Get in front of buyers like Apotex

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →